Pharma-Bio Serv
Through the investors’ lenses
0 of 3 cleared1 of 6 criteria
Each of these investors has said in public what they look at before buying. Click a name to see how this company measures up — a tick where it passes one of their tests, a cross where it does not.
Warren Buffett 0/3
| Measure | PBSV | Checked against | |
|---|---|---|---|
| Owner earnings | $-47.24k | positive | ✗ |
| Return on equity | -0.8% | US median 2.8% | ✗ |
| Debt to equity | — | US median 0.57x | — |
| Operating margin | -7.1% | US median 3.1% | ✗ |
Passes 0 of 3. These are the measures Warren Buffett published, applied to Pharma-Bio Serv’s own figures — their criteria, not their view of this company. What he looks at, and why →
Benjamin Graham 1/2
| Measure | PBSV | Checked against | |
|---|---|---|---|
| Current ratio | 7.70x | 2.00x published | ✓ |
| Long-term debt to working capital | — | 1.00x published | — |
| Positive earnings, ten years running | 0 yrs | 10 published | ✗ |
Passes 1 of 2. These are the measures Benjamin Graham published, applied to Pharma-Bio Serv’s own figures — their criteria, not their view of this company. What he looks at, and why →
Peter Lynch 0/1
| Measure | PBSV | Checked against | |
|---|---|---|---|
| Debt to equity | — | US median 0.57x | — |
| Net margin | -1.1% | US median 2.0% | ✗ |
Passes 0 of 1. These are the measures Peter Lynch published, applied to Pharma-Bio Serv’s own figures — their criteria, not their view of this company. What he looks at, and why →
| Basis | Payout | Why |
|---|---|---|
| GAAP earnings | negative | whyLost $0.0040 per share — no earnings to pay from. |
| Operating cash flow | negative | whyOperations consumed $215k of cash rather than producing any, so no ratio exists. |
| Free cash flow | negative | whyOperating cash flow was $222k short of capital spending, so no ratio exists. The dividend was not funded from free cash flow this year. |
Nothing is marked as applying, deliberately — no basis produces a ratio. Earnings, operating cash flow and free cash flow are all negative, so there is no denominator to divide the dividend by. That is not a gap in the data; it is the answer. The dividend was funded from something other than the money the business made this year — borrowing, cash on hand, or asset sales — and the filing will say which.
Coverage rating 40 / 100 — Tight. ? Peer standing 4/50Direction 30/30Stability 6/20
Free cash flow payout, last 3 years
| Fiscal year | Payout |
|---|---|
| 2023-10-31 | 91.5% |
| 2021-10-31 | 217.6% |
| 2020-10-31 | 118.3% |
8% of the 289 industrials here pay out more — at the demanding end.
The arithmetic
- GAAP earnings — dividends declared per share $0.0749 ÷ diluted EPS $-0.0040
- Operating cash flow — dividends paid $1.72m ÷ operating cash flow $-215k
- Free cash flow — dividends paid $1.72m ÷ (operating cash flow $-215k − capex $7k)
Where the figures came from
- 10-K filed 2026-01-29 · accession 0001654954-26-000710
Every one is public at sec.gov and free to check. That is the point — you should not have to take our word for any of it.
Caveats on this company
- DPS derived from dividends paid ($0.07); no per-share tag filed
Computed by an open pipeline reading SEC XBRL directly. If any number here looks wrong to you, tell us — that is more useful to us than agreement.
Also on: rated tight · when it files.
Who else looks like this
Every figure above is computed from Pharma-Bio Serv’s own filing, and every company here is measured the same way. Screen all of them on any of these twelve measures, or on the rules four investors published — free, and nothing you screen leaves your browser.
A subscription screens every company on this site at once, and turns a whole portfolio into one document — what that adds.